In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...
Read More
In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...
Read More
In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...
Read More
In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...
Read More
In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read More
In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...
Read More
In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2 x 4 doses) with or without blinatumomab (Blincyto) in patients with...
Read More
In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...
Read More
In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients. Some background Hodgkin lymphoma (HL) is a cancer that...
Read More
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read More
In a nutshell This study assessed the effectiveness and safety of geptanolimab (GB226) in relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL). The authors concluded that geptanolimab showed promising activity and manageable safety in these patients. Some background Peripheral T cell lymphoma (PTCL) is a rare subtype of non-Hodgkin...
Read More
